TY - JOUR
T1 - Synthesis and Characterization of Transition-State Analogue Inhibitors against Human DNA Methyltransferase 1
AU - Lamiable-Oulaidi, Farah
AU - Harijan, Rajesh K.
AU - Shaffer, Karl J.
AU - Crump, Douglas R.
AU - Sun, Yan
AU - Du, Quan
AU - Gulab, Shivali A.
AU - Khan, Ashna A.
AU - Luxenburger, Andreas
AU - Woolhouse, Anthony D.
AU - Sidoli, Simone
AU - Tyler, Peter C.
AU - Schramm, Vern L.
N1 - Funding Information:
We thank Drs. Niusha Mahmoodi and Ashleigh Paparella for insightful scientific discussions and technical support. This work was supported by research grant GM041916 from the National Institutes of Health and by the New Zealand MBIE Endeavour Fund Program RTVU 1808.
Publisher Copyright:
© 2022 American Chemical Society. All rights reserved.
PY - 2022/4/14
Y1 - 2022/4/14
N2 - Hypermethylation of CpG regions by human DNA methyltransferase 1 (DNMT1) silences tumor-suppression genes, and inhibition of DNMT1 can reactivate silenced genes. The 5-azacytidines are approved inhibitors of DNMT1, but their mutagenic mechanism limits their utility. A synthon approach from the analogues of S-adenosylhomocysteine, methionine, and deoxycytidine recapitulated the chemical features of the DNMT1 transition state in the synthesis of 16 chemically stable transition-state mimics. Inhibitors causing both full and partial inhibition of purified DNMT1 were characterized. The inhibitors show modest selectivity for DNMT1 versus DNMT3b. Active-site docking predicts inhibitor interactions with S-adenosyl-l-methionine and deoxycytidine regions of the catalytic site, validated by direct binding analysis. Inhibitor action with purified DNMT1 is not reflected in cultured cells. A partial inhibitor activated cellular DNA methylation, and a full inhibitor had no effect on cellular DNA methylation. These compounds provide chemical access to a new family of noncovalent DNMT chemical scaffolds for use in DNA methyltransferases.
AB - Hypermethylation of CpG regions by human DNA methyltransferase 1 (DNMT1) silences tumor-suppression genes, and inhibition of DNMT1 can reactivate silenced genes. The 5-azacytidines are approved inhibitors of DNMT1, but their mutagenic mechanism limits their utility. A synthon approach from the analogues of S-adenosylhomocysteine, methionine, and deoxycytidine recapitulated the chemical features of the DNMT1 transition state in the synthesis of 16 chemically stable transition-state mimics. Inhibitors causing both full and partial inhibition of purified DNMT1 were characterized. The inhibitors show modest selectivity for DNMT1 versus DNMT3b. Active-site docking predicts inhibitor interactions with S-adenosyl-l-methionine and deoxycytidine regions of the catalytic site, validated by direct binding analysis. Inhibitor action with purified DNMT1 is not reflected in cultured cells. A partial inhibitor activated cellular DNA methylation, and a full inhibitor had no effect on cellular DNA methylation. These compounds provide chemical access to a new family of noncovalent DNMT chemical scaffolds for use in DNA methyltransferases.
UR - http://www.scopus.com/inward/record.url?scp=85127592042&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127592042&partnerID=8YFLogxK
U2 - 10.1021/acs.jmedchem.1c01869
DO - 10.1021/acs.jmedchem.1c01869
M3 - Article
C2 - 35324190
AN - SCOPUS:85127592042
SN - 0022-2623
VL - 65
SP - 5462
EP - 5494
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 7
ER -